NEUROCRINE BIOSCIENCES INC
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
NBIX$169.14+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Income and Comprehensive Income
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
AND COMPREHENSIVE INCOME
| Three Months EndedMarch 31, | ||
|---|---|---|
| (in millions, except per share data) | 2025 | 2024 |
| Revenues: | ||
| Net product sales | $563.7 | $509.0 |
| Collaboration revenues | 8.9 | 6.3 |
| Total revenues | 572.6 | 515.3 |
| Operating expenses: | ||
| Cost of revenues | 9.2 | 7.5 |
| Research and development | 263.2 | 159.4 |
| Acquired in-process research and development | 0.1 | 6.0 |
| Selling, general, and administrative | 276.5 | 243.1 |
| Total operating expenses | 549.0 | 416.0 |
| Operating income | 23.6 | 99.3 |
| Other (expense) income: | ||
| Unrealized (loss) gain on equity investments | (30.6) | 1.6 |
| Charges associated with convertible senior notes | — | (88.7) |
| Investment income and other, net | 21.7 | 22.3 |
| Total other expense, net | (8.9) | (64.8) |
| Income before provision for income taxes | 14.7 | 34.5 |
| Provision for (Benefit from) income taxes | 6.8 | (8.9) |
| Net income | $7.9 | $43.4 |
| Foreign currency translation adjustments, net of tax | 1.5 | (0.5) |
| Unrealized gain (loss) on available-for-sale debt securities, net of tax | 1.7 | (3.2) |
| Comprehensive income | $11.1 | $39.7 |
| Earnings per share: | ||
| Basic | $0.08 | $0.43 |
| Diluted | $0.08 | $0.42 |
| Weighted-average shares outstanding: | ||
| Basic | 99.7 | 99.8 |
| Diluted | 102.5 | 103.6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.